Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tonix Pharmaceuticals Holding (TNXP) Return on Equity (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Return on Equity over the past 3 years, most recently at 0.51% for Q4 2025.

  • Quarterly results put Return on Equity at 0.51% for Q4 2025, up 77.0% from a year ago — trailing twelve months through Dec 2025 was 0.51% (up 77.0% YoY), and the annual figure for FY2025 was 0.63%, up 49.0%.
  • Return on Equity for Q4 2025 was 0.51% at Tonix Pharmaceuticals Holding, down from 0.49% in the prior quarter.
  • Over the last five years, Return on Equity for TNXP hit a ceiling of 0.47% in Q2 2025 and a floor of 2.44% in Q3 2024.
  • Median Return on Equity over the past 3 years was 0.99% (2024), compared with a mean of 1.12%.
  • Biggest five-year swings in Return on Equity: fell -25bps in 2024 and later soared 195bps in 2025.
  • Tonix Pharmaceuticals Holding's Return on Equity stood at 1.04% in 2023, then dropped by -24bps to 1.28% in 2024, then surged by 60bps to 0.51% in 2025.
  • The last three reported values for Return on Equity were 0.51% (Q4 2025), 0.49% (Q3 2025), and 0.47% (Q2 2025) per Business Quant data.